These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6769937)

  • 21. Plasma glucose and free fatty acids modulate the secretion of growth hormone, but not prolactin, in the rhesus and Java monkey.
    Quabbe HJ; Bunge S; Walz T; Bratzke B
    J Clin Endocrinol Metab; 1990 Apr; 70(4):908-15. PubMed ID: 2108186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
    Tanner CM; Chhablani R; Goetz CG; Klawans HL
    Neurology; 1985 Jun; 35(6):918-21. PubMed ID: 3889707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term study of pergolide in Parkinson's disease.
    Jankovic J
    Neurology; 1985 Mar; 35(3):296-9. PubMed ID: 3974887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
    Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
    Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pergolide therapy for Parkinson's disease: neurobehavioral changes.
    Stern Y; Mayeux R; Ilson J; Fahn S; Cote L
    Neurology; 1984 Feb; 34(2):201-4. PubMed ID: 6538009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists.
    Goldstein M; Engel J; Lieberman A; Regev I; Bystritsky A; Mino S
    J Neural Transm Suppl; 1983; 18():257-63. PubMed ID: 6135744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pergolide mesylate in the treatment of Parkinson's disease resistant to other treatments. First Italian experience].
    Pezzoli G; Zecchinelli A; Mariani C; Reganati P; Scarlato G
    Clin Ter; 1991 Jan; 136(1):39-45. PubMed ID: 1826872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
    Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
    Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1177-9. PubMed ID: 6404378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 31. Different prolactin, thyrotropin, and thyroxine responses after prolonged intermittent or continuous infusions of thyrotropin-releasing hormone in rhesus monkeys.
    Pavasuthipaisit K; Norman RL; Ellinwood WE; Oyama TT; Baughman WL; Spies HG
    J Clin Endocrinol Metab; 1983 Mar; 56(3):541-8. PubMed ID: 6401761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction between beta-endorphin and alpha-melanocyte-stimulating hormone in the control of prolactin and luteinizing hormone secretion in the primate.
    Wardlaw SL; Ferin M
    Endocrinology; 1990 Apr; 126(4):2035-40. PubMed ID: 2156679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A; Goldstein M; Leibowitz M; Neophytides A; Kupersmith M; Pact V; Kleinberg D
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic activation of dopamine receptors in the female infantile rat: effect on hypophyseal hormones and on the onset of puberty.
    de Mengido IM; Becú-Villalobos D; Díaz G; Libertun C
    Endocrinology; 1989 Feb; 124(2):746-53. PubMed ID: 2492218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats.
    Gräf KJ; Neumann F; Horowski R
    Endocrinology; 1976 Mar; 98(3):598-605. PubMed ID: 1261489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma.
    Bowsher RR; Apathy JM; Compton JA; Wolen RL; Carlson KH; DeSante KA
    Clin Chem; 1992 Oct; 38(10):1975-80. PubMed ID: 1394981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nursing induces a biphasic release of prolactin in rhesus monkeys.
    Frawley LS; Mulchahey JJ; Neill JD
    Endocrinology; 1983 Feb; 112(2):558-61. PubMed ID: 6848363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.